AbbVie Research and Development Expenses 2010-2024 | ABBV

AbbVie research and development expenses for the twelve months ending September 30, 2024 were $7.944B, a 5.39% increase year-over-year.

  • AbbVie annual research and development expenses for 2023 were $7.675B, a 17.9% increase from 2022.
  • AbbVie annual research and development expenses for 2022 were $6.51B, a 5.95% decline from 2021.
  • AbbVie annual research and development expenses for 2021 were $6.922B, a 8.51% increase from 2020.

AbbVie Research and Development Expenses 2010-2024 | ABBV

  • AbbVie annual research and development expenses for 2023 were $7.675B, a 17.9% increase from 2022.
  • AbbVie annual research and development expenses for 2022 were $6.51B, a 5.95% decline from 2021.
  • AbbVie annual research and development expenses for 2021 were $6.922B, a 8.51% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B